The complaint alleges that Replimune failed to disclose critical feedback from the Food and Drug Administration concerning the design of a study included in its Biologics License Application. Plaintiffs argue that by omitting these concerns, the company issued materially misleading statements that artificially influenced share prices throughout the defined class period.

The DJS Law Group is currently organizing the litigation and seeking shareholders who suffered losses during this window. While the firm is soliciting lead plaintiffs to represent the class, participation in any potential recovery does not strictly require an official appointment. Investors have until October 5, 2026, to take action in the case against the NASDAQ-listed firm.